7.45
+0.09(+1.22%)
Currency In USD
| Previous Close | 7.36 |
| Open | 7.36 |
| Day High | 7.49 |
| Day Low | 7.08 |
| 52-Week High | 7.89 |
| 52-Week Low | 2.3 |
| Volume | 219,027 |
| Average Volume | 312,849 |
| Market Cap | 635.22M |
| PE | -14.33 |
| EPS | -0.52 |
| Moving Average 50 Days | 5.85 |
| Moving Average 200 Days | 4.02 |
| Change | 0.09 |
If you invested $1000 in Alpha Tau Medical Ltd. (DRTS) since IPO date, it would be worth $737.62 as of February 11, 2026 at a share price of $7.45. Whereas If you bought $1000 worth of Alpha Tau Medical Ltd. (DRTS) shares 3 years ago, it would be worth $1,981.38 as of February 11, 2026 at a share price of $7.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
GlobeNewswire Inc.
Jan 29, 2026 2:00 PM GMT
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
GlobeNewswire Inc.
Jan 06, 2026 2:00 PM GMT
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treat
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
GlobeNewswire Inc.
Jan 05, 2026 2:00 PM GMT
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted